President Donald Trump's proposed 2018 budget cuts $5.8 billion from the National Institutes of Health (NIH), about 20% of its current budget. While these numbers represent a request to Congress and not a final agreement, the cuts are a dramatic statement against science as a priority for the administration and for our country.
These cuts, if implemented, may have a greater negative impact on the stem cell research field than the restrictions implemented by former President Bush. Ongoing NIH funding is critical to all biomedical research, including ours at The New York Stem Cell Foundation. Cutting these funds is a major risk for all research, and threatens to slow down or stop potentially lifesaving experiments while also put at risk the jobs of many scientists across the country.
The President has also proposed significant budget cuts to the NIH and other scientific agencies for the remainder of this year’s budget. These drastic measures would be a major step back for the advancement of science and medicine in the United States.
Politico spoke with NYSCF CEO Susan L. Solomon about the proposed cuts, read the story here (firewalled) >>
- Dr. Ilana Katz-Sand, an assistant professor of neurology at Mount Sinai Medical Center in New York City and a member of the MS Microbiome Consortium. Current research projects include studies on the mechanisms of neuronal degeneration in progressive MS, an investigation of the role of the gut microbiome in MS, as well as a clinical trial for neuromyelitis optica. In addition to her own projects, Dr. Katz Sand participates in MS clinical trials. She is also involved in education, teaching residents and medical students at Mount Sinai, and lectures on MS and NMO to other physicians and patients.
- Dr. Patrizia Casaccia, recently named the founding director of the CUNY Advanced Science Research Center’s (ASRC) Neuroscience Initiative. Her research at the ASRC focuses on glial cell biology, the study of those cells most common the central nervous system. She maintains an affiliation with the Icahn School of Medicine at Mount Sinai, where she has previously served as professor with the Department of Neuroscience, Neurology and Department of Genomics and Multiscale Biology. She also directed the Center of Excellence for Myelin Repair within the Friedman Brain Institute.
- Dr. Catarina Quinzii, an Assistant Professor at Columbia University Medical Center, with expertise in neurology, neuroscience and genetics, and also holds an appointment in the Division of Neuromuscular Medicine. Her research involves investigating the role of mitochondria dysfunction in disease progression.
- Dr. Matilde Inglese, an Associate Professor of Neurology, Radiology and Neuroscience at Mount Sinai School of Medicine. Her lab focuses on understanding the pathophysiological mechanisms leading to disease onset and progression in patients with multiple sclerosis. She serves as a member of the National Institute of Health study sections, and is also a member of the American Academy of Neurology and the International Society of Magnetic Resonance in Medicine.
- Dr. Valentina Fossati, an Investigator at the New York Stem Cell Foundation since 2011. She was a recipient of the NYSCF - Druckenmiller Fellowship in 2009. Her current research focuses on using induced pluripotent stem cell modeling for understanding neurodegeneration in MS.
The NYSCF Global Stem Cell Array was a central talking point in both an exclusive interview and digital panel with The Regenerative Medicine Network. NYSCF Senior Vice President of Research Dr. Scott Noggle spoke with RegMedNet about how he became interested in stem cell research, NYSCF's growth in the past eleven years including construction and launch of the NYSCF Array, and NYSCF’s ongoing efforts to continually improve stem cell production and derivation using cutting edge automation.
In addition to the interview with Dr. Noggle, NYSCF’s Dr. Daniel Paull, Vice President, Automation Systems & Stem Cell Biology, highlighted the importance of the NYSCF Array in a RegMedNet digital panel discussing induced pluripotent stem cell derivation and applications in research. The panel covered challenges in stem cell derrivation, future potential applications in regenerative medicine, and regulatory challenges. Fellow panelists included Lia Kent of Biological Industries USA, Dr. Yvonne Mica of Thermo Fisher Scientific, and Dr. Fiona Watt of Centre for Stem Cells & Regenerative Medicine at King’s College London.
Adult cells can be reprogrammed into stem cells through a technique called somatic cell nuclear transfer where the nucleus of the adult cell is transferred into an enucleated oocyte or egg cell. However, this process often causes the cell to stop dividing and growing. NYSCF – Robertson Stem Cell Investigator Dr. Dieter Egli and a team of researchers at Columbia University Medical Center studied why this developmental arrest happens. Published in Nature Cell Biology, the scientists showed that cell-type-specific features of cell cycle progression are different enough from one another to prevent the transition from one cell type to another during reprogramming, independent of gene expression.
It is not yet known which type of stem cell derivation will result in the best cells for use in research, drug toxicity testing, and future cell replacement therapies. Understanding the causes and affects of reprogramming techniques on DNA and genome expression is a critical step towards better research, and new treatments and therapies.
NYSCF's latest paper could have important implications for human reproductive technologies. The scientists showed proof of principle that genome transfer can rescue developmentally incompetent eggs, making them viable for use in reproduction. NYSCF Research Institute scientist Dr. Mitsutoshi Yamada and NYSCF – Robertson Investigator Dr. Dieter Egli used a mouse model to investigate the causes of the decline in developmental potential in aged oocytes.
Through a battery of complementary experiments transferring the genomes of differently aged mouse oocytes post ovulation, the scientists showed that the developmental decline in oocytes is primarily due to abnormal function of cytoplasmic factors, not to deterioration of the genome. This research was published in Stem Cell Reports.